Skip to main content
Premium Trial:

Request an Annual Quote

German Dx Firm Taps N-of-One to Provide Clinical Interpretation for NGS Testing

Premium

NEW YORK (GenomeWeb) – N-of-One said this week that it has been selected by CeGaT to interpret data from its next-generation sequencing-based oncology tests.

Under the terms of the agreement, N-of-One will analyze data from CeGaT's NGS panel which tests for more than 550 cancer genes. The company's interpretation results will include biological and clinical information about mutations found in the tumor as well as access to potential therapeutic strategies and clinical trials.

Financial and other terms of the deal were not disclosed

N-of-One's customer base includes Cedars-Sinai Medical Center. The company also has a co-marketing agreement with Appistry that allows both companies sell each other's content, technology, and services.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.